Sotrovimab clinical trials
Also written VIR-7831 and GSK4182136.
How each study uses sotrovimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the sotrovimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- 17 Dec 2021 · Xevudy · EMEA/H/C/005676 (EMA; now withdrawn)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2021 (8)
| Year | Studies |
|---|---|
| 2020 | 5 |
| 2021 | 8 |
| 2022 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 9
Vir Biotechnology, Inc. (5) · GlaxoSmithKline (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · University of Oxford (2) · Cambridge University Hospitals NHS Foundation Trust (1) · Sophia Koo, M.D. (1) · Eli Lilly and Company (1) · Fred Hutchinson Cancer Center (1)
Often tested with
Tested in the same studies.
Bamlanivimab (2) · Bebtelovimab (2) · Hydroxychloroquine (2) · Molnupiravir (2) · Nirmatrelvir and ritonavir drug combination (2) · Cilgavimab and tixagevimab drug combination (1) · Ensovibep (1) · Lufotrelvir (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test sotrovimab.
- Jan 2027Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)Phase 2 · University of Oxford
Studies
Open first, then newest update. How each study uses sotrovimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- Randomised Evaluation of COVID-19 TherapyRecruitingPhase 3University of OxfordNCT04381936Written as SotrovimabHow we know
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)RecruitingPhase 2University of OxfordNCT05041907Written as SotrovimabHow we know
- Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19CompletedPhase 4GlaxoSmithKlineNCT05305651Written as SotrovimabHow we know
- PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -VCompletedPhase 2/3Cambridge University Hospitals NHS Foundation TrustNCT04870333Written as SotrovimabHow we know
- Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB StudyTerminatedPhase 1Fred Hutchinson Cancer CenterNCT05135650Written as SotrovimabHow we know
- Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)TerminatedPhase 1Vir Biotechnology, Inc.NCT05280717Written as sotrovimabHow we know
- A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 in Immunocompromised IndividualsCompletedPhase 2Sophia Koo, M.D.NCT05210101Written as SotrovimabHow we know
- A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian ParticipantsCompletedPhase 1Vir Biotechnology, Inc.NCT04988152Written as sotrovimabHow we know
- Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.TerminatedPhase 3Vir Biotechnology, Inc.NCT04913675Written as sotrovimabHow we know
- Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19TerminatedPhase 2GlaxoSmithKlineNCT05124210Written as SotrovimabHow we know
- VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT05780281Written as VIR-7831How we know
- ACTIV-3: Therapeutics for Inpatients With COVID-19CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT04501978Written as VIR-7831How we know
- UPMC OPTIMISE-C19 Trial, a COVID-19 StudyTerminatedPhase 4Erin McCrearyNCT04790786Written as SotrovimabHow we know
- Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19CompletedPhase 2Vir Biotechnology, Inc.NCT04779879Written as Sotrovimab (Gen1)How we know
- VIR-7831 for the Early Treatment of COVID-19 in OutpatientsCompletedPhase 2/3Vir Biotechnology, Inc.NCT04545060Written as VIR-7831 (sotrovimab)How we know
- Non-inferiority Trial on Monoclonal Antibodies in COVID-19TerminatedPhase 3Azienda Ospedaliera Universitaria Integrata VeronaNCT05205759Written as SotrovimabHow we know
- A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 IllnessCompletedPhase 2Eli Lilly and CompanyNCT04634409Written as VIR-7831How we know
As the comparator · 2 — what is tested is compared with sotrovimab
Codes
What other systems call sotrovimab · ClinicalTrials.gg INT001486
- MeSH (NLM) C000711967sotrovimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 1MTK0BPN8VSOTROVIMABConfirmed FDA, NLM, Wikidata
- RxNorm 2550731One source FDA
- Wikidata Q106943333SotrovimabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C177059SotrovimabOne source FDA
- DrugBank DB16355One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000711967 | sotrovimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 1MTK0BPN8V | SOTROVIMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2550731 | — | One source FDA |
| Wikidata | Q106943333 | Sotrovimab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C177059 | Sotrovimab | One source FDA |
| DrugBank | DB16355 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.